Literature DB >> 23890931

Characteristics, drug combinations and dosages of primary care patients with uncontrolled ambulatory blood pressure and high medication adherence.

Larissa Grigoryan1, Valory N Pavlik2, David J Hyman2.   

Abstract

Most studies on the prevalence and determinants of resistant hypertension (RH) do not account for white coat hypertension, medication non-adherence, or use of suboptimal treatment dosages. We studied the characteristics, drug combinations, and dosages of patients on at least three antihypertensives of different classes who had uncontrolled blood pressure on 24-hour ambulatory blood pressure monitoring and high medication adherence measured by electronic monitoring. The data were collected as part of the baseline measures of a hypertension control trial. Of 140 monitored primary care patients, all with uncontrolled office blood pressure, 69 (49%) were on at least three antihypertensives of different classes. Of these 69, 15 (22%) were controlled on ambulatory blood pressure monitoring, 20 (29%) were uncontrolled and non-adherent, leaving only 34 (49%) adherent to their medications and having uncontrolled ambulatory hypertension (uncontrolled RH). Thirty-one (91%) of the 34 uncontrolled RH patients were prescribed a diuretic, of which 24 were on hydrochlorothiazide 25 mg. Less than half of the patients on angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, or calcium channel blocker were prescribed maximal doses of these agents. Half of the RH can be attributed to white coat effect and poor medication adherence, and all of the remaining patients were on apparently suboptimal drug combinations and/or dosages. Primary care physicians need to be educated regarding the optimal treatment of RH.
Copyright © 2013 American Society of Hypertension. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Resistant hypertension; drug dosage; electronic monitoring; medication adherence; white-coat hypertension

Mesh:

Substances:

Year:  2013        PMID: 23890931      PMCID: PMC3883386          DOI: 10.1016/j.jash.2013.06.004

Source DB:  PubMed          Journal:  J Am Soc Hypertens        ISSN: 1878-7436


  29 in total

1.  Incidence and prognosis of resistant hypertension in hypertensive patients.

Authors:  Stacie L Daugherty; J David Powers; David J Magid; Heather M Tavel; Frederick A Masoudi; Karen L Margolis; Patrick J O'Connor; Joe V Selby; P Michael Ho
Journal:  Circulation       Date:  2012-02-29       Impact factor: 29.690

2.  Predictors of antihypertensive medication adherence in two urban health-care systems.

Authors:  Larissa Grigoryan; Valory N Pavlik; David J Hyman
Journal:  Am J Hypertens       Date:  2012-03-22       Impact factor: 2.689

3.  Prevalence and correlates of low medication adherence in apparent treatment-resistant hypertension.

Authors:  Marguerite R Irvin; Daichi Shimbo; Devin M Mann; Kristi Reynolds; Marie Krousel-Wood; Nita A Limdi; Daniel T Lackland; David A Calhoun; Suzanne Oparil; Paul Muntner
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-08-03       Impact factor: 3.738

4.  Effect of a physician uncertainty reduction intervention on blood pressure in uncontrolled hypertensives--a cluster randomized trial.

Authors:  David J Hyman; Valory N Pavlik; Anthony J Greisinger; Wenyaw Chan; Jose Bayona; Carol Mansyur; Victor Simms; James Pool
Journal:  J Gen Intern Med       Date:  2011-10-27       Impact factor: 5.128

5.  Prevalence and clinical profile of resistant hypertension among treated hypertensive subjects.

Authors:  Jessica Barochiner; José Alfie; Lucas S Aparicio; Paula E Cuffaro; Marcelo A Rada; Margarita S Morales; Carlos R Galarza; Gabriel D Waisman
Journal:  Clin Exp Hypertens       Date:  2012-11-13       Impact factor: 1.749

Review 6.  Beta-blockers for hypertension.

Authors:  Charles Shey Wiysonge; Hazel A Bradley; Jimmy Volmink; Bongani M Mayosi; Anthony Mbewu; Lionel H Opie
Journal:  Cochrane Database Syst Rev       Date:  2012-08-15

7.  High prevalence of cardiac and extracardiac target organ damage in refractory hypertension.

Authors:  C Cuspidi; G Macca; L Sampieri; I Michev; M Salerno; V Fusi; B Severgnini; S Meani; F Magrini; A Zanchetti
Journal:  J Hypertens       Date:  2001-11       Impact factor: 4.844

8.  Clinical differences between resistant hypertensives and patients treated and controlled with three or less drugs.

Authors:  Alejandro de la Sierra; José R Banegas; Anna Oliveras; Manuel Gorostidi; Julián Segura; Juan J de la Cruz; Pedro Armario; Luis M Ruilope
Journal:  J Hypertens       Date:  2012-06       Impact factor: 4.844

Review 9.  Optimizing blood pressure control in hypertension: the need to use ABPM.

Authors:  Roland E Schmieder; Marina V Lehmann; Stephanie Schmidt
Journal:  Blood Press       Date:  2012-10-04       Impact factor: 2.835

10.  Patterns of nonadherence to antihypertensive therapy in primary care.

Authors:  Larissa Grigoryan; Valory N Pavlik; David J Hyman
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-10-26       Impact factor: 3.738

View more
  15 in total

1.  [Therapy-resistant and therapy-refractory arterial hypertension].

Authors:  M Wallbach; M J Koziolek
Journal:  Internist (Berl)       Date:  2018-06       Impact factor: 0.743

2.  White-Coat Effect Is Uncommon in Patients With Refractory Hypertension.

Authors:  Mohammed Siddiqui; Eric K Judd; Suzanne Oparil; David A Calhoun
Journal:  Hypertension       Date:  2017-07-10       Impact factor: 10.190

3.  Masked Uncontrolled Hypertension Is Not Attributable to Medication Nonadherence.

Authors:  Mohammed Siddiqui; Eric K Judd; Tanja Dudenbostel; Bin Zhang; Pankaj Gupta; Maciej Tomaszewski; Prashanth Patel; Suzanne Oparil; David A Calhoun
Journal:  Hypertension       Date:  2019-07-22       Impact factor: 10.190

4.  Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association.

Authors:  Robert M Carey; David A Calhoun; George L Bakris; Robert D Brook; Stacie L Daugherty; Cheryl R Dennison-Himmelfarb; Brent M Egan; John M Flack; Samuel S Gidding; Eric Judd; Daniel T Lackland; Cheryl L Laffer; Christopher Newton-Cheh; Steven M Smith; Sandra J Taler; Stephen C Textor; Tanya N Turan; William B White
Journal:  Hypertension       Date:  2018-11       Impact factor: 10.190

5.  Prevalence of pseudoresistant hypertension due to inaccurate blood pressure measurement.

Authors:  Hemal Bhatt; Mohammed Siddiqui; Eric Judd; Suzanne Oparil; David Calhoun
Journal:  J Am Soc Hypertens       Date:  2016-03-30

Review 6.  Refractory Hypertension: A Novel Phenotype of Antihypertensive Treatment Failure.

Authors:  Tanja Dudenbostel; Mohammed Siddiqui; Suzanne Oparil; David A Calhoun
Journal:  Hypertension       Date:  2016-04-18       Impact factor: 10.190

7.  Reserpine Substantially Lowers Blood Pressure in Patients With Refractory Hypertension: A Proof-of-Concept Study.

Authors:  Mohammed Siddiqui; Hemal Bhatt; Eric K Judd; Suzanne Oparil; David A Calhoun
Journal:  Am J Hypertens       Date:  2020-08-04       Impact factor: 2.689

Review 8.  Medication adherence and resistant hypertension.

Authors:  D J Hyman; V Pavlik
Journal:  J Hum Hypertens       Date:  2014-09-11       Impact factor: 3.012

9.  Antihypertensive Medication Adherence and Confirmation of True Refractory Hypertension.

Authors:  Mohammed Siddiqui; Eric K Judd; Tanja Dudenbostel; Pankaj Gupta; Maciej Tomaszewski; Prashanth Patel; Suzanne Oparil; David A Calhoun
Journal:  Hypertension       Date:  2019-12-09       Impact factor: 10.190

10.  The prevalence and predictors of resistant hypertension in high-risk overweight and obese patients: A cross-sectional study based on the 2017 ACC/AHA guidelines.

Authors:  Faris Haddadin; Karan Sud; Alba Munoz Estrella; Sananda Moctezuma; Lingling Wu; Joshua Berookhim; Claire Huang Lucas; Dipal Patel; Edgar Argulian
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-08-26       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.